Video encyclopedia



Why I'm More Excited About MindMed's 18-MC than its LSD treatments


Nicotinic antagonist | Wikipedia audio article


MindMed Patents 18MC? A new Psychedelic ETF? [ Plus more MMED/MMEDF, LOBE, CYBIN & COOL Updates]


Ken Alper at the European Ibogaine Forum in Porto, 2018


Entheo-Science / Dana Beal : Mechanism of nerve growth & Ibogaine’s Immune Modulatory Effects

(–)-18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective at reducing self-administration of morphine, cocaine, methamphetamine, nicotine and sucrose. 18-MC is a α3β4 nicotinic antagonist and, in contrast to ibogaine, has no affinity at the α4β2 subtype nor at NMDA-channels nor at the serotonin transporter, and has significantly reduced affinity for sodium channels and for the σ receptor, but retains modest affinity for μ-opioid receptors where it acts as an antagonist, and κ-opioid receptors. The sites of action in the brain include the medial habenula, interpeduncular nucleus, dorsolateral tegmentum and basolateral amygdala. It has also been shown to produce anorectic effects in obese rats, most likely due to the same actions on the reward system which underlie its anti-addictive effects against drug addiction.
Explore contextually related video stories in a new eye-catching way. Try Combster now!